Q-omics provides the consensus-scored RNF122 profile across patient tissues and cancer cell-line models. RNF122 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RNF122 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RNF122 RNA expression shows 16,409 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, KIRC, and ACC as cancer lineages where RNF122 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF122 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF122 survival associations across molecular data types. RNF122 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF122 RNA expression–survival associations across cancer types. High RNF122 expression shows unfavorable associations in THCA, ACC, MESO and LGG, but favorable associations in UVM and UCEC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RNF122 RNA expression.
This table summarizes RNF122 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF122. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF122 shows lower tumor expression in LUAD, BLCA, LUSC and KICH and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher RNF122 RNA expression in tumor versus normal tissue (log2 FC = +0.889, t-test p < 0.001).
This table shows molecular features associated with RNF122 in patient tissues and cancer cell lines. In patient samples, RNF122 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF122 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS.
